Document is current
Any future updates will be listed below
-
Authors
Bartoló-Ibars, Ariadna
Aran, Andrea
Johansson, Alexandra M https://orcid.org/0000-0003-4779-4648
Ortiz-Maldonado, Valentín https://orcid.org/0000-0003-4699-6862
Klein-González, Nela
Alonso-Saladrigues, Anna
James, Eddie https://orcid.org/0000-0002-7217-5729
Urbano-Ispizua, Alvaro
Rives, Susana
Delgado, Julio https://orcid.org/0000-0002-5157-4376
González-Navarro, Europa Azucena
Kwok, William W
Juan, Manel https://orcid.org/0000-0002-3064-1648
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03144583 at ClinicalTrials.govnct03144583 at ClinicalTrials.govDocuments that mention this clinical trial
Factors associated with the clinical outcome of patients with relapsed/refractory CD19<sup>+</sup> acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
https://doi.org/10.1136/jitc-2021-003644
P09.05 Immunogenicity induced by the academic chimeric antigen receptor CAR19 (ARI-0001) in patients with CD19-positive relapsed/refractory B-cell malignancies recruited into the CART19-BE-01 clinical trial
https://doi.org/10.1136/jitc-2020-itoc7.105
T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes
https://doi.org/10.1136/jitc-2024-010792
Documents that mention this clinical trial
Factors associated with the clinical outcome of patients with relapsed/refractory CD19<sup>+</sup> acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
https://doi.org/10.1136/jitc-2021-003644
P09.05 Immunogenicity induced by the academic chimeric antigen receptor CAR19 (ARI-0001) in patients with CD19-positive relapsed/refractory B-cell malignancies recruited into the CART19-BE-01 clinical trial
https://doi.org/10.1136/jitc-2020-itoc7.105
T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes
https://doi.org/10.1136/jitc-2024-010792
-
Funding
Funding for this research was provided by:
AGAUR Generalitat de Catalunya (2021-SGR-01162)
Fundación Científica Asociación Española Contra el Cáncer (ATTRA236784)
RICORS-TERAV+ (RD24/0014/0001)
"la Caixa” Foundation (LCF/PR/SP23/52950004)
Instituto de Salud Carlos III, Ministerio de Sanidad, Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa” (PI18/00775)
Instituto de Salud Carlos III, Ministerio de Sanidad, Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa” (PICI18/00012)
- License Information
